T. Pascoal

Plasma eMTBR-tau as a robust biomarker for Alzheimer's disease tangle pathology up to 10 years before death

Scalable and accessible biomarkers of neurofibrillary tangle pathology are needed for Alzheimer's disease prognosis, diagnosis and monitoring. Here, we show that a blood-based immunoassay for an endogenously-cleaved eMTBR-tau fragment of tau protein is strongly associated with autopsy-diagnosed Alzheimer neuropathologi...

Age at Diagnosis and Clinical and Genetic Profiles Among Adults With Attention-Deficit/Hyperactivity Disorder

Key Points Question Do demographic, clinical, and genetic profiles of adults diagnosed with attention-deficit/hyperactivity disorder (ADHD) in adulthood differ from adults diagnosed with ADHD in childhood or adolescence, and how do profiles of both groups compare with matched controls without ADHD? Findings In this cro...

Tau‐PET correlates of mild behavioral impairment in preclinical and prodromal Alzheimer's disease: A head‐to‐head comparison of Flortaucipir and MK6240

Abstract INTRODUCTION We compared the association between mild behavioral impairment (MBI) and first‐ versus second‐generation tau‐positron emission tomography (PET) tracers in preclinical and prodromal Alzheimer's disease (AD). METHODS We assessed 110 individuals with head‐to‐head [18F]MK6240 and [18F]Flortaucipir tau...

A Harmonized Visual Reading Framework for Tau PET Staging in Alzheimer Disease

Key Points Question Can a harmonized visual reading framework enable reliable, tracer-agnostic staging of tau positron emission tomography (PET) pathology for clinical use? Findings In this multicenter cross-sectional study of 681 participants scanned with multiple tau PET radiotracers, a 5-class harmonized visual read...

Metabolic brain network reorganization precedes clinical conversion in Alzheimer’s disease

Pharmacological management in frontotemporal dementia and patient outcomes: a retrospective cohort study using the TriNetX platform

Symptomatic treatment remains the cornerstone of therapeutic management in frontotemporal dementia (FTD), as disease-modifying therapies are currently unavailable. However, several medications originally developed for other neuropsychiatric conditions may represent potentially harmful medications (PHMs) in FTD. This st...

Astrocyte reactivity identifies p-tau217-positive individuals at elevated risk of cognitive decline across the Alzheimer’s disease continuum

It is shown that elevated plasma GFAP significantly modulates the association between p-tau217 and both cross-sectional cognitive severity and longitudinal clinical decline, and support that astrocyte reactivity is associated with greater cognitive impairment and faster clinical decline among individuals with elevated...

Association of age with clinical progression across plasma p-tau217 levels

These findings support further evaluation of age-contextualized plasma p-tau217 interpretation for prognosis and trial enrichment and support further evaluation of age-contextualized plasma p-tau217 interpretation for prognosis and trial enrichment.

Altered T1w/T2w-FLAIR Ratio in White Matter Hyperintensities as an Indicator of Structural Integrity Loss: Association with Alzheimer’s Disease and Vascular Dementia

Residualized WMH T1w/T2w-FLAIR ratio captures lesion-specific microstructural variation missed by volumetric measures, consistent with vascular-gliotic injury in VD and coexisting amyloid-linked demyelination in AD.

Differential associations of tau extent and load with brain metabolic and cognitive dysfunction in Alzheimer's disease

Across regions and networks, SEOT performed similarly or better than tau load in predicting metabolic dysfunction and may improve diagnostic characterisation and prediction of cognitive impairment beyond [18F]FDG-PET.

Blood-based biomarkers of Alzheimer’s disease and neurodegeneration in an indigenous African cohort using both Simoa and NULISA platforms

In low- and middle-income countries, Alzheimer’s disease (AD) constitutes a growing public health burden. However, AD biomarkers research remains underrepresented in African populations. This study assesses core biomarkers of AD and their relevance in the African context as potential aid in clinical diagnosis. Nigerian...

Association Between Plasma GFAP and Medial Temporal Atrophy and Cognition in Amyloid-Negative Cerebrovascular Disease.

In Aβ-negative cognitively impaired individuals with high cerebrovascular burden, elevated plasma GFAP is associated with medial temporal atrophy and cognitive decline, suggesting GFAP may capture astrocyte-reactivity relevant to vascular cognitive impairment beyond amyloid pathology.